Astellas and Audax Biosciences Enter Exclusive Option and License Agreement
The agreement covers DAX-044, an immune-targeted IL-12 antibody-cytokine fusion for immuno-oncology.
The agreement covers DAX-044, an immune-targeted IL-12 antibody-cytokine fusion for immuno-oncology.